Publications

Correcting for intra-experiment variation in Illumina BeadChip data is necessary for robust gene-expression profiles.

Kitchen RR, Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JMS.

BMC Genomics (2010) 11:134

Dynamic Changes in breast cancer gene expression in vivo predict response to tamoxifen thereapy in patients with breast cancer

Taylor K, Sims AH, Liang L, Faratian D, Muir M, Walker G, Kuske B, Dixon JM, Harrison D, Cameron DA, Langdon SP

Breast Cancer Research 2010 12(3) R39

Functional genetic polymorphisms in the aromatase gene CYP19 vary the resonse of breast cancer patients to neoadjuvant therapy with aromatase inhibitors

Wang L, Ellsworth K, Moon I, Pelleymounter L, Eckloff B, Martin Y, Fridley B, Jenkins G, Batzler A, Suman V, Ravi S, Dixon JM, Miller W, Wieben E, Buzdar A, Weinshilboum, Ingle J

Cancer Research 2010 70(1) 319:328

Gene Expression Profiling of response to mTOR Inhibitor Everolimus in pre-operatively treated post-menopausal women with estrogen receptor positive breast cancer

Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JMS

Breast Cancer Research & Treatment 2010 Jul 122(2) 419:28

Genes discriminating between breast cancers responsive or resistant tot he aromatase inhibitor, letrozole

Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, Dixon JM

European Journal of Clinical Oncology 2010 2(2) June 2010

The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers.

R Hrstka, R Nenutil, A Fourtouna, MM Maslon, C Naughton, S Langdon, E Murray, A Larionov, K Petrakova, P Muller, MJ Dixon, TR Hupp and B Vojtesek.

Oncogene (2010) 29, 4838–4847; doi:10.1038/onc.2010.228.

Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.

Authors: Miller WR, Larionov A, Anderson TJ, Walker JR, Krause A, Evans DB, Dixon JM.

Cancer (2008) 112, 689-694.

Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer

Authors: Dixon JM.

Expert Rev Anticancer Ther. (2008) 453-63.

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.

Authors: Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, et al.

Pharmacogenet Genomics (2007) 17, 813-826

Aromatase inhibitors: cellular and molecular effects.

Authors: Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM.

J Steroid Biochem Mol Biol (2005) 95, 83-89.

A standard curve based method for relative real time PCR data processing.

Authors: Larionov A, Krause A, Miller W

BMC Bioinformatics (2005) 6:62

Aromatase in skeletal muscle.

Authors: Larionov AA, Vasyliev DA, Mason JI, Howie AF, Berstein LM, Miller WR.

J Steroid Biochem Mol Biol (2003) 84, 485-492

Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues.

Authors: Larionov AA, Berstein LM, Miller WR.

J Steroid Biochem Mol Biol (2002) 81, 57-64